These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 21169255

  • 1. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
    Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.
    Clin Cancer Res; 2010 Dec 15; 16(24):6029-39. PubMed ID: 21169255
    [Abstract] [Full Text] [Related]

  • 2. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.
    PLoS One; 2012 Dec 15; 7(2):e31331. PubMed ID: 22355357
    [Abstract] [Full Text] [Related]

  • 3. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
    Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM.
    J Transl Med; 2011 Aug 11; 9():133. PubMed ID: 21834980
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
    Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.
    Oncotarget; 2014 Aug 30; 5(16):6788-800. PubMed ID: 25216518
    [Abstract] [Full Text] [Related]

  • 11. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
    Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR.
    Br J Cancer; 2012 Apr 10; 106(8):1386-94. PubMed ID: 22415236
    [Abstract] [Full Text] [Related]

  • 12. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
    Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.
    Mol Cancer Ther; 2009 Aug 10; 8(8):2204-10. PubMed ID: 19671762
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.
    J Exp Clin Cancer Res; 2014 Jun 17; 33(1):52. PubMed ID: 24939055
    [Abstract] [Full Text] [Related]

  • 14. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.
    Oncogene; 2012 Jul 05; 31(27):3213-22. PubMed ID: 22037215
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Jul 05; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 16. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Jan 31; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 18. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB, Kolekar S, Jabed A, Jaynes P, Shih JH, Wang Q, Flanagan JU, Rewcastle GW, Baguley BC, Shepherd PR.
    BMC Cancer; 2021 Feb 06; 21(1):136. PubMed ID: 33549048
    [Abstract] [Full Text] [Related]

  • 19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.